LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

LB Pharmaceuticals (NASDAQ:LBRX) had its price target lifted by Stifel Nicolaus from $35.00 to $40.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would indicate a potential upside of 67.79% from the stock’s current price.

Several other research analysts have also weighed in on the company. Roth Mkm initiated coverage on LB Pharmaceuticals in a research report on Friday, January 9th. They set a “buy” rating and a $31.00 price target on the stock. Weiss Ratings reaffirmed a “sell (e)” rating on shares of LB Pharmaceuticals in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, LB Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.

LB Pharmaceuticals Trading Down 2.8%

Shares of NASDAQ:LBRX opened at $23.84 on Friday. LB Pharmaceuticals has a 52 week low of $13.36 and a 52 week high of $27.55. The stock has a market cap of $603.15 million and a P/E ratio of -39.08. The company has a 50 day moving average price of $23.59.

LB Pharmaceuticals (NASDAQ:LBRX) last announced its earnings results on Thursday, March 26th. The company reported ($0.45) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.45).

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. California State Teachers Retirement System acquired a new stake in shares of LB Pharmaceuticals in the 4th quarter valued at $26,000. Bank of America Corp DE acquired a new position in LB Pharmaceuticals during the third quarter worth $27,000. Russell Investments Group Ltd. acquired a new position in LB Pharmaceuticals during the fourth quarter worth $34,000. Strs Ohio bought a new position in LB Pharmaceuticals during the fourth quarter valued at about $76,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of LB Pharmaceuticals in the fourth quarter worth about $91,000.

Key Stories Impacting LB Pharmaceuticals

Here are the key news stories impacting LB Pharmaceuticals this week:

• Positive Sentiment: Initiated pivotal Phase 3 NOVA-2 trial for LB-102 in acute schizophrenia, moving the program into late‑stage development and de‑risking the clinical pathway. LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102
• Positive Sentiment: New Phase 2 (NOVA-1) analyses presented at SIRS show LB-102 produced statistically significant, likely direct improvements in cognitive performance versus placebo — a clinically meaningful differentiation if confirmed in Phase 3. LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial
• Positive Sentiment: Multiple SIRS presentations and encore sessions underline broad evidence across symptom domains (positive, negative, cognitive), increasing the perceived clinical value of LB-102. LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial (GlobeNewswire)
• Positive Sentiment: Stifel raised its price target from $35 to $40 and maintains a Buy rating — a notable analyst vote of confidence that can support upside if clinical and regulatory progress continues. Stifel raises price target
• Positive Sentiment: Strong cash position: ~$295.2M in cash, equivalents and investments as of 12/31/25 plus ~$100M private placement; company says runway into Q2 2029 — reduces near‑term financing risk for ongoing trials. Q4 and FY2025 Results and Corporate Update
• Neutral Sentiment: Q4 EPS of ($0.45) matched consensus — earnings met expectations but did not provide an upside catalyst; full financials and guidance appear consistent with the company’s stated runway. Quarterly Results PDF
• Negative Sentiment: Cautionary forward‑looking statements and standard clinical/regulatory risks remain — Phase 3 outcomes, approval risk and commercialization execution are not guaranteed, and the company has a limited operating history and historical losses. Risk Factors and Cautionary Note

About LB Pharmaceuticals

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.